Comprehensive Explorations of CCL28 in Lung Adenocarcinoma Immunotherapy and Experimental Validation

References

• Brody H. Lung cancer. Nature. 2020;587(7834):S7. doi:10.1038/d41586-020-03152-0
   PubMed Web of Science ®Google Scholar
• Succony L, Rassl DM, Barker AP, McCaughan FM, Rintoul RC. Adenocarcinoma spectrum lesions of the lung: detection, pathology and treatment strategies. Cancer Treat Rev. 2021;99:102237. doi:10.1016/j.ctrv.2021.102237
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299–311. doi:10.1016/S0140-6736(16)30958-8
   PubMed Web of Science ®Google Scholar
• Rossi A, Di Maio M. Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles. Expert Rev Anticancer Ther. 2016;16(6):653–660. doi:10.1586/14737140.2016.1170596
   PubMed Web of Science ®Google Scholar
• Zhang M, Ma J, Guo Q, Ding S, Wang Y, Pu H. CD8(+) T cell-associated gene signature correlates with prognosis risk and immunotherapy response in patients with lung adenocarcinoma. Front Immunol. 2022;13:806877. doi:10.3389/fimmu.2022.806877
   PubMedGoogle Scholar
• Zhou L, Xu Q, Huang L, et al. Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer. Cancer Letters. 2021;500:163–171. doi:10.1016/j.canlet.2020.11.049
   PubMedGoogle Scholar
• Vilgelm AE, Richmond A. Chemokines modulate immune surveillance in tumorigenesis, metastasis, and response to immunotherapy. Front Immunol. 2019;10:333. doi:10.3389/fimmu.2019.00333
   PubMed Web of Science ®Google Scholar
• Miller MC, Mayo KH. Chemokines from a structural perspective. Int J Mol Sci. 2017;18(10):2088. doi:10.3390/ijms18102088
   PubMed Web of Science ®Google Scholar
• Wunderlich CM, Ackermann PJ, Ostermann AL, et al. Obesity exacerbates colitis-associated cancer via IL-6-regulated macrophage polarisation and CCL-20/CCR-6-mediated lymphocyte recruitment. Nat Commun. 2018;9(1):1646. doi:10.1038/s41467-018-03773-0
   PubMedGoogle Scholar
• Tas F, Karabulut S, Serilmez M, Karabulut M, Duranyildiz D. Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer. Cancer Chemother Pharmacol. 2016;77(1):127–131. doi:10.1007/s00280-015-2886-5
   PubMedGoogle Scholar
• Facciabene A, Peng X, Hagemann IS, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature. 2011;475(7355):226–230. doi:10.1038/nature10169
   PubMed Web of Science ®Google Scholar
• Ren L, Yu Y, Wang L, Zhu Z, Lu R, Yao Z. Hypoxia-induced CCL28 promotes recruitment of regulatory T cells and tumor growth in liver cancer. Oncotarget. 2016;7(46):75763–75773. doi:10.18632/oncotarget.12409
   PubMed Web of Science ®Google Scholar
• Ayers M, Lunceford J, Nebozhyn M, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Investig. 2017;127(8):2930–2940. doi:10.1172/JCI91190
   PubMed Web of Science ®Google Scholar
• Fu J, Li K, Zhang W, et al. Large-scale public data reuse to model immunotherapy response and resistance. Genome Med. 2020;12(1):21. doi:10.1186/s13073-020-0721-z
   PubMed Web of Science ®Google Scholar
• Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14:7. doi:10.1186/1471-2105-14-7
   PubMed Web of Science ®Google Scholar
• Ren X, Chen X, Zhang X, et al. Immune microenvironment and response in prostate cancer using large population cohorts. Front Immunol. 2021;12:686809. doi:10.3389/fimmu.2021.686809
   PubMedGoogle Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545–15550. doi:10.1073/pnas.0506580102
   PubMed Web of Science ®Google Scholar
• Rodescu D. Lung cancer. Med Clin North Am. 1977;61(6):1205–1218. doi:10.1016/S0025-7125(16)31256-1
   PubMedGoogle Scholar
• Wu D, Yin Z, Ji Y, et al. Identification of novel autophagy-related lncRNAs associated with a poor prognosis of colon adenocarcinoma through bioinformatics analysis. Sci Rep. 2021;11(1):8069. doi:10.1038/s41598-021-87540-0
   PubMedGoogle Scholar
• Yu L, Shen H, Ren X, et al. Multi-omics analysis reveals the interaction between the complement system and the coagulation cascade in the development of endometriosis. Sci Rep. 2021;11(1):11926. doi:10.1038/s41598-021-90112-x
   PubMed Web of Science ®Google Scholar
• Wei X, Dong Y, Chen X, et al. Construction of circRNA-based ceRNA network to reveal the role of circRNAs in the progression and prognosis of metastatic clear cell renal cell carcinoma. Aging. 2020;12(23):24184–24207. doi:10.18632/aging.104107
   PubMedGoogle Scholar
• Zhang M, Yang W, Wang P, et al. CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer. Nat Commun. 2020;11(1):6119. doi:10.1038/s41467-020-19973-6
   PubMed Web of Science ®Google Scholar
• Hoelzinger DB, Smith SE, Mirza N, Dominguez AL, Manrique SZ, Lustgarten J. Blockade of CCL1 inhibits T regulatory cell suppressive function enhancing tumor immunity without affecting T effector responses. J Immunol. 2010;184(12):6833–6842. doi:10.4049/jimmunol.0904084
   PubMed Web of Science ®Google Scholar
• Liu C, Yang Y, Chen C, et al. Environmental eustress modulates β-ARs/CCL2 axis to induce anti-tumor immunity and sensitize immunotherapy against liver cancer in mice. Nat Commun. 2021;12(1):5725. doi:10.1038/s41467-021-25967-9
   PubMedGoogle Scholar
• Yang H, Zhang Q, Xu M, et al. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis. Mol Cancer. 2020;19(1):41. doi:10.1186/s12943-020-01165-x
   PubMed Web of Science ®Google Scholar
• Tanaka A, Sakaguchi S. Targeting Treg cells in cancer immunotherapy. Eur J Immunol. 2019;49(8):1140–1146. doi:10.1002/eji.201847659
   PubMed Web of Science ®Google Scholar
• Li L, Liu X, Sanders KL, et al. TLR8-mediated metabolic control of human treg function: a mechanistic target for cancer immunotherapy. Cell Metabol. 2019;29(1):103–123.e105. doi:10.1016/j.cmet.2018.09.020
   PubMed Web of Science ®Google Scholar
• Bai F, Zhang P, Fu Y, et al. Targeting ANXA1 abrogates Treg-mediated immune suppression in triple-negative breast cancer. J Immunother Cancer. 2020;8(1):e000169. doi:10.1136/jitc-2019-000169
   PubMed Web of Science ®Google Scholar
• La Fleur L, Botling J, He F, et al. Targeting MARCO and IL37R on immunosuppressive macrophages in lung cancer blocks regulatory T cells and supports cytotoxic lymphocyte function. Cancer Res. 2021;81(4):956–967. doi:10.1158/0008-5472.CAN-20-1885
   PubMed Web of Science ®Google Scholar
• Redin E, Garmendia I, Lozano T, et al. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation. J Immunother Cancer. 2021;9(3):e001496. doi:10.1136/jitc-2020-001496
   PubMedGoogle Scholar
• Nakamura N, Shi X, Darabi R, Li Y. Hypoxia in cell reprogramming and the epigenetic regulations. Front Cell Dev Biol. 2021;9:609984. doi:10.3389/fcell.2021.609984
   PubMedGoogle Scholar
• Suthen S, Lim CJ, Nguyen PHD, et al. Hypoxia-driven immunosuppression by Treg and type-2 conventional dendritic cells in HCC. Hepatology. 2022;76:1329–1344. doi:10.1002/hep.32419
   PubMedGoogle Scholar
• Liu B, Wei C. Hypoxia induces overexpression of CCL28 to recruit treg cells to enhance angiogenesis in lung adenocarcinoma. J Environ Pathol. 2021;40(1):65–74. doi:10.1615/JEnvironPatholToxicolOncol.2020035859
   PubMedGoogle Scholar
• Shi LZ, Wang R, Huang G, et al. HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med. 2011;208(7):1367–1376. doi:10.1084/jem.20110278
   PubMed Web of Science ®Google Scholar
• Huang G, Tao L, Shen S, Chen L. Hypoxia induced CCL28 promotes angiogenesis in lung adenocarcinoma by targeting CCR3 on endothelial cells. Sci Rep. 2016;6:27152. doi:10.1038/srep27152
   PubMedGoogle Scholar